Maxygen Announces Issuance of Patent Covering Methods of Template-Based Recombination to Produce Chimeric Genes
REDWOOD CITY, Calif., Nov. 26 /PRNewswire/ -- Maxygen, Inc. (Nasdaq: MAXY - news) today announced the issuance of U.S. patent 6,319,713, which covers recombination-based methods using single-stand templates to produce novel genes and proteins. Such methods include the Rachitt technology that Enchira Biotechnology (Nasdaq: ENBC - news) claimed to have developed. In a recently concluded arbitration between Maxygen and Enchira, Maxygen was determined to be the exclusive owner of the Rachitt technology, and Enchira was barred from using, licensing or otherwise commercializing the Rachitt technology until 2017. The issuance of this patent confirms Maxygen's ownership of the inventions described in this patent, and reinforces the result of the arbitration.
``This patent illustrates two important points regarding Maxygen's intellectual property,'' said Michael Rabson, Ph.D., Maxygen's General Counsel. ``First, we remain committed to securing and enforcing intellectual property rights for our inventions. Second, Maxygen has pioneered the development of recombination-based directed evolution technologies, and our intellectual property rights in this area are broad, and more extensive than some may have anticipated.''
Maxygen currently owns or has licenses to over 45 U.S. patents relating to its MolecularBreeding(TM) technologies, and to over 450 patent applications filed worldwide. Maxygen, headquartered in Redwood City, California, is focused on creating novel products using its integrated proprietary technologies for human therapeutics and industrial applications... |
